Oncology drug repurposing as a blueprint for Alzheimer's therapy
{{output}}
Alzheimer's disease (AD) imposes substantial personal, social, and economic burdens, yet current therapies provide only modest slowing of clinical decline. Recent approvals of amyloid-targeting antibodies confirm target engagement but also expose the limitati... ...
